Skip to Content
Merck
CN

Vestibular effects of lidocaine intratympanic injection in rats.

Human & experimental toxicology (2014-02-08)
H H Lee, M J Kim, Y K Jo, J Y Kim, G C Han
ABSTRACT

When lidocaine is locally delivered into the inner ear, it rapidly paralyzes the peripheral vestibular afferent neurons and induces unilateral vestibular loss. The goals of this study were to explore the possibility of developing intratympanic injection (IT) of lidocaine as a modality for treating acute vertigo. To evaluate the minimum concentration required, latent time, action duration, and possibility of lidocaine IT readministration to the vestibular system, we compared the development of horizontal nystagmus after IT of 2, 4, 6, 8, and 10% lidocaine solutions in rats. To identify the induction of vestibular compensation, c-Fos-like protein expression was observed in the vestibular nucleus. Results of our investigation showed that lidocaine IT concentrations greater than 4% induced vestibular hyporeflexia in the injected ear. In order to induce hyporeflexia 4 and 6% lidocaine solutions could also be repeatedly injected. Regardless of concentration, effects of the lidocaine IT dissipated gradually over time. Our findings could be used to develop novel methods for symptom control in vestibular disorder patients.

MATERIALS
Product Number
Brand
Product Description

Lidocaine, European Pharmacopoeia (EP) Reference Standard
USP
Lidocaine, United States Pharmacopeia (USP) Reference Standard
Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Urethane, ≥99%
Sigma-Aldrich
Urethane, ≥99.0% (GC)
Supelco
Urethane, analytical standard